Sai Reddy
Vorsitzender bei deepCDR Biologics AG
Profil
Sai Reddy is the founder of Engimmune Therapeutics AG, which was founded in 2021.
He is currently the Chairman at deepCDR Biologics AG and a Venture Partner at Pureos Partners AG.
Dr. Reddy holds a doctorate degree from École Polytechnique Fédérale de Lausanne, conferred in 2008, and an undergraduate degree from Northwestern University, conferred in 2003.
Aktive Positionen von Sai Reddy
| Unternehmen | Position | Beginn |
|---|---|---|
deepCDR Biologics AG
 deepCDR Biologics AG Miscellaneous Commercial ServicesCommercial Services Part of Alloy Therapeutics LLC, deepCDR Biologics AG is a Swiss biotechnology company that develops biotechnologies. The company is based in Basel, Switzerland. deepCDR Biologics was acquired by Alloy Therapeutics LLC on December 09, 2021. | Vorsitzender | - |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Private Equity Investor | - |
Ehemalige bekannte Positionen von Sai Reddy
| Unternehmen | Position | Ende |
|---|---|---|
Engimmune Therapeutics AG
 Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Gründer | - |
Ausbildung von Sai Reddy
| Northwestern University | Undergraduate Degree |
| École Polytechnique Fédérale de Lausanne | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
deepCDR Biologics AG
deepCDR Biologics AG Miscellaneous Commercial ServicesCommercial Services Part of Alloy Therapeutics LLC, deepCDR Biologics AG is a Swiss biotechnology company that develops biotechnologies. The company is based in Basel, Switzerland. deepCDR Biologics was acquired by Alloy Therapeutics LLC on December 09, 2021. | Commercial Services |
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Technology Services |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Finance |
